key: cord-0961929-oysiiala authors: Meghana, Aruru; Aparna, Yerramilli; Chandra, Sekar M.; Sanjeev, Sharma title: Emergency preparedness and response (EP&R) by pharmacy professionals in India: Lessons from the COVID-19 pandemic and the way forward date: 2020-04-25 journal: Res Social Adm Pharm DOI: 10.1016/j.sapharm.2020.04.028 sha: 86d9e984833b6091b0e205be4521bb9669a17ed7 doc_id: 961929 cord_uid: oysiiala Abstract The COVID-19 pandemic highlights the importance of Emergency Preparedness & Response (EP&R) education, training, capacity building and infrastructure development in India. During the pandemic, pharmacy professionals (PPs) in India have continued to provide medications, supplies and services. India's public-private healthcare system is complex and of variable quality. Lacunae in pharmacy education, training, and lack of resolution around pharmacist roles present challenges in providing health services to patients. Such lack of differentiation creates challenges around role specifications and appropriate placement of PPs in patient care and on EP&R task forces or representation at the policy level. This study aimed to gain rapid insights from PPs in India regarding their roles and preparedness for the COVID-19 pandemic. An online survey comprising 20 questions regarding EP&R and Operations management was developed using the Qualtrics® survey software and administered to a sample of PPs. Survey results indicate that PPs were actively involved in essential pharmacy services despite minimal EP&R training. Based on lessons learned during COVID-19, lacunae in knowledge, training and regulations were identified and recommendations are provided to broaden PP roles and enable them to be better prepared and actively engaged in EP&R for future emergencies. COVID-19 (SARS Cov-2 virus) was identified in Wuhan, China in December 2019 and rapidly spread to 177 countries. As of April 14, 2020, there were over 1.9 million confirmed COVID-19 cases and 117,000 deaths globally. 1 While most countries saw a sudden rise in cases, India, the second most populous country with 1.38 billion people (~17.7% of the world's population) has reported 10,000 cases with 393 deaths as of April 14, 2020. 2 The first COVID-19 case in India was identified on Jan 30, 2020 in the Southern state of Kerala. 3 Community transmission is reported to be slow and limited. In the initial days since the first confirmed COVID-19 case, there were few testing sites with a few hundred tests conducted nationwide daily. As of April 10, 2020, the Indian Council of Medical Research designated 146 government testing laboratories and 67 private laboratories for COVID-19 testing. 3 On March 24, 2020, a countrywide lockdown was announced and went into effect immediately. This lockdown was abrupt and resulted in a mass exodus of 120 million individuals (mostly migrant and seasonal laborers). 4 This mass exodus has been compared to the partition of India wherein, 14-15 million individuals were displaced. Results from this mass exodus in terms of COVID-19 transmission or infections in rural areas (where access to healthcare services tends to be far less than urban areas), may likely result in not only overwhelming the fragile and fragmented healthcare system but also pushing them into poverty and starvation. India's healthcare system is a complex network of public and private providers. The public sector offers healthcare at low or no cost but is perceived as being unreliable, of low quality and generally not the first choice, unless one cannot afford private care. [5] [6] [7] In 2018, India had 8.5 medical doctors, 17 nurses, 1.8 dentists and 8.8 pharmaceutical personnel per 10,000 population. 8 10 Pharmacists lack provider status and recognition. 11 However, community pharmacists are one of the most accessible health care professionals with potential for providing pharmaceutical care and health information, especially during pandemics like COVID-19. The number of pharmacists -clinical and staff, working in hospitals have increased steadily in the past decade with the advent of the Pharm.D program and due to hospital accreditation requirements. Lacunae in pharmacy education, training, and lack of resolution around pharmacist roles present challenges in providing health services to patients. This lack of differentiation creates challenges around role specifications and appropriate placement of clinically trained Pharmacy Professionals (PP) along with challenges of their incorporation in Emergency Preparedness & Response (EP&R). PPs around the world have significant roles to play in emergencies as outlined by the FIP guidance, 12 Joint Statement by Pharmacy organizations in the U.S, 13 relevant publications in the RSAP journal 14, 16 and the proposed PEPR framework. 15 Since PP roles in India are often varied, limited to dispensing, and less involved in clinical decision making, we present opportunities and challenges for PPs in the COVID-19 pandemic as identified through literature and PP responses to a survey developed for this study titled 'Preparedness of Pharmacists in India to address the COVID-19 pandemic'. An online survey comprising 20 questions regarding Emergency Preparedness and Operations management was developed using the Qualtrics® survey software and was disseminated to a convenient sample of known pharmacy networks in India through the WhatsApp messaging platform. 24 PPs from 7 states (1 north, 1 west, 5 south) responded to the informal survey. Average age was 35 years (range: 24-58 years) and average years of practice were 5.83 (range: 1-27 years). Of the 24 PPs, there were 13 Pharm.Ds, 5 M.Pharm, and 4 joint M.Pharm-Pharm.D. 11 respondents work in academia ,2 in clinics and 11 in community pharmacies . Survey results are presented in Table 1 . Incomplete surveys were deleted from the analysis. Of those PPs reporting undergoing COVID-19 training, 87% said that the training lasted between 1-3 hours. 11 PPs sought training on mask selection and fitting. PPs emphasized social distancing and isolation as strategies for infection control and reported increased demand for hydroxychloroquine, chloroquine, azithromycin, and antivirals, but did not report price increases for these drugs. PPs also reported screening patients for fever (67%), cough (42%), emotional and anxiety issues (33%) alongwith numerous actions taken towards social distancing such as telephone consultations, educating patients, and disseminating information on handwashing and mask usage. PPs reported that their organizations were taking steps to address fear and anxiety among staff. (See Fig. 1 and 2) PPs in India are beginning to experience similar challenges as exemplified in other articles in the RSAP journal. Opportunities exist to reframe the roles of PPs and include them in EP&R planning at the policy level and beyond as discussed below: In our survey, PPs responded that they would like to be trained and better prepared for COVID-19 and other emergencies. Engaging PPs in policy making and developing a cadre of EP&R professionals to serve and respond is the first step to address this gap in India's EP&R to COVID-19 and beyond. A welcome initial step was taken by the Ministry of Health and Family Welfare by requesting the Pharmacy Council of India, the accrediting body for Pharm.D education to prepare a state-wise national list of pharmacists who can be enrolled as part of the COVID warriors health force and by making the State Pharmacy Councils as nodal offices (https://covidwarriors.gov.in/). Inclusion of PPs in policy making is encouraged to enable professional expansion (for e.g. in the U.S., many states have implemented collaborative practice agreements allowing PPs to bill for services such as point-ofcare testing and immunizations). 17 Training through continuing education programs is needed to keep PPs updated with current knowledge and practices. Such training could include EP&R modules to address medical and pharmaceutical waste management, minimize contagion, and provide accurate information to patients and communities. Currently, few schools of pharmacy address public health and community health in their curricula. Universities, accreditation bodies and educational boards should consider including EP&R in curricula to address the lacuna in training. 18 In response to emergencies, the National Disaster Management Authority (NDMA) 19 was enacted in 2005 to address disaster preparedness and response, including a National Disaster Response Force (NDRF) 20 that has 12 battalions trained and equipped to respond to natural and man-made disasters. Currently, there is no mention of PPs in the Act or among the NDRF battalions. It is recommended that PPs be included in the NDRF battalions and on task force planning and responses to chemical, biological, radiological, nuclear emergencies. Further, the Indian Council of Medical Research received U.S $500 million from the World Bank's fast track COVID-19 facility. PPs should be included as stakeholders in the development of EP&R measures through this program. 21 Supply chain: Supply chains in India are currently sub-optimally designed, lack end-to-end visibility, and have been slow to adopt digital technologies. 22 Challenges in procurement and distribution are likely to result from disruptions to supply chains. PPs could play an important role in estimating supplies during emergencies and when lockdowns are mandated to ensure sufficient stocks of medications for chronic illnesses, anti-infectives, PPEs, and commonly used OTC products are available. Pharmacies in India ran out of their limited PPE stock within days of the first COVID-19 case being identified. This surge in demand could not be met by small community pharmacies with limited capacity. 23 Collaboration and cooperation among pharmacies may help ensure uninterrupted medications and supplies, particularly in hard-to-reach areas, to ensure continuity-of-care and prevent contagion. PPs may extend their involvement to recommend safe and effective therapeutic alternatives while prioritizing limited supplies and medications for patients based on their clinical needs. Patient management: Pharmacists as essential healthcare workers have continued to remain accessible and provide medications and supplies to their communities. Currently, COVID-19 patients are being treated in only government hospitals. 24 However, when the number of cases increase, the private sector would be required to admit patients and provide necessary treatments. Major tertiary care hospitals have emergency preparedness plans and hospital pharmacists should be included in the planning and execution of such plans to ensure optimal medication safety and usage (Box 1). Workplace safety: India's 1.3 billion population was abruptly placed under lockdown for 21 days initially from March 24th onwards to prevent community spread. At the time of writing this paper, the duration of lockdown was extended by 2 more weeks. There were reports of healthcare professionals being harassed and at the receiving end of violent and uncivil behavior by public and law enforcement officials. 25 All healthcare workers should be protected, and measures need to be taken in order to ensure their physical safety as well as ensuring that they have adequate PPEs to protect themselves from contagion. Expanding PP roles: PPs roles in India incorporate dispensing, stocking, manufacturing, quality assurance, clinical trial management, academia, and research. With the advent of the Pharm.D, these roles could be further expanded into provision of patient care and population health interventions such as screenings for infectious and certain noncommunicable diseases, addressing medication adherence, evaluating medication utilization, providing stewardship on antimicrobial resistance, leading to additional support to the healthcare sector. For instance, collaborative practice agreements (CPPA) with physicians would enable PP to assess medication adherence, develop patient care plans including medication safety, monitor health outcomes, among others. 17 Ethics and Integrity: Reports in media indicating challenges of hoarding hydroxychloroquine, chloroquine, azithromycin, vitamin C by healthcare professionals and public emerged in several parts of the country 26 following ICMR guidelines on their prophylaxis in COVID-19. 27 In response, the Ministry of Health and Family Welfare imparted Schedule H1 status for Hydroxychloroquine (https://www.mohfw.gov.in/pdf/RevisedNational ClinicalManagementGuidelineforCOVID1931032020.pdf) thereby limiting its demand and inappropriate use. India's pharmaceutical manufacturing sector was directed to increase the output of these drugs to meet surges in demand. Steps were taken to ensure that local demands were met prior to exports to countries in need. In our study, hoarding or price increases were not reported. Nevertheless, rigorous training on professional ethics and integrity needs to be reinforced in pharmacy students and healthcare professionals through ongoing and continuing education. Post introduction of the 2008 Pharm.D program in India, the number of research projects and awareness activities in hospital and community settings have increased. 28 Many schools of pharmacy regularly organize activities on World Health days (e.g. World TB day, No Tobacco day) to improve awareness and educate the general public. However, programs on EP&R such as Point of Dispensing (POD) drills, 29 stockpiles, 30 public awareness campaigns are yet to be seen. Additional research and evaluation is needed, particularly in EP&R, to highlight and demonstrate the value of PPs in emergencies. The COVID-19 pandemic has revealed lacunae in the healthcare system, education, and training of PPs for EP&R in India. A systematic review of the population's needs is needed to develop a PP EP&R framework to enable effective responses in emergencies. Formalizing such EP&R responses through education, training, and research would further serve to expand PPs roles and recognition as healthcare professionals in India. While every country's situation and responses are unique, lessons learned in EP&R, particularly relevant for Indian PPs are provided below based on several papers addressing the topic ( Table 2) . Tracking India's Coronavirus Spread India's Coronavirus Lockdown Means Millions Of Migrant Workers Can't Earn A Living: Goats and Soda: NPR Health systems in India Quality of health care in India: Challenges, priorities, and the road ahead Challenges to healthcare in India -The five A's Density of physicians (total number per 1000 population, latest available year). WHO Say Pharmacists as Gadkari Opens Old Wound FIP Health Advisory Coronavirus SARS-CoV-2 / COVID-19 Pandemic: Information and interim guidelines for pharmacists and the pharmacy workforce Pharmacist Advocacy Groups Call for New Action to Enhance COVID-19 Patient Care | AACP COVID-19 in Colombia endpoints. Are we different, like Europe? Res Soc Adm Pharm Pharmacy Emergency Preparedness and Response (PEPR) framework for expanding pharmacy professionals' roles and contributions to emergency preparedness and response during the COVID-19 pandemic and beyond Recommendations and guidance for providing pharmaceutical care services during COVID-19 pandemic: A China perspective Practice Agreement and Pharmacists' Patient Care Services. 8. Cent Dis Control National Disaster Management Authority. Government of India National Disaster Response Force. Ministry of Home Affairs. Government of India Preliminary Stakeholder Engagement Plan (SEP) -India COVID-19 Emergency Response and Health Systems Preparedness Project (P173836) Supply Chains in India: A Reality Check Roles of the clinical pharmacist during the COVID-19 pandemic Advisory for Hospitals and Medical Education Institutions Doctors Come Under Attack in India as Coronavirus Stigma Grows -Bloomberg Hydroxychloroquine becomes a Schedule H1 drug as hoarding leads to shortage -The Economic Times Indian council of medical research. Recommendation for empiric use of hydroxychloroquine for prophylaxis of SARS-CoV-2 infection The changing roles of pharmacists in community pharmacies: Perception of reality in India Health Care Closed Points of Dispensing | CDC Strategic National Stockpile We thank the responders of the COVID-19 survey. We thank Mr. Ashok Eku and Dr. Arun Santhosh in helping us understand the scenario in India during this epidemic. Many thanks to Mr. Satheesh Gottipati for reviewing the manuscript. Supplementary data related to this article can be found at https:// doi.org/10.1016/j.sapharm.2020.04.028.